FDA
-
-
-
-
-
-
-
Kamada signs $50M plasma supply deal, sales to begin in Q4 2026
-
-
-
-
-
-
-
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
-
-
-
-
-
-
-
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
-
-
-
-
-
-
-
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
-
-
-
-
-
-
-
Kamada receives FDA approval for Houston plasma collection center
-
-
-
-
-
-
-
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity
-
-
-
-
-
-
-
Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
-
330,123 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

